Antigen‐Presenting Hybrid Colloidal Crystal Clusters for Promoting T cells Expansion. Issue 14 (12th March 2021)

• Record Type: Journal Article
• Authors: Shou, Xin; Zhang, Hui; Wu, Dan; Zhong, Liping; Ni, Dong; Kong, Tiantian; Zhao, Yongxiang; Zhao, Yuanjin
• Is Part Of: Small. Volume 17:Issue 14(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-12
• Subjects: colloidal crystals -- hydrogels -- immunotherapy -- scaffolds -- T cells; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.202006955
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract: T cell based‐immunotherapy has been a powerful strategy to eradicate tumor cells in clinical trials. Effectively expanding the therapeutic T cells for clinical demand is still a challenge. Here, artificial antigen‐presenting scaffolds are created for T cell ex vivo expansion. The antigen‐presenting hybrid colloidal crystal clusters (HCCCs) with multiple stimuli are generated by internal encapsulation with prosurvival cytokines and surface decoration with activating antibodies to CD3ε and CD28, respectively. With the large loading capacity endowed by their abundant nanoporous structures, the antigen‐presenting HCCCs can constantly release prosurvival cytokine IL‐2. It is found that following the direct and multiple stimulations, the antigen‐presenting HCCCs can effectively promote the expansion of T cells, which exhibits robust antitumor activity in vitro. Thus, the antigen‐presenting HCCCs provide a novel expansion platform for clinical manufacturing of T cells. Abstract : A novel kind of antigen‐presenting scaffolds loaded with prosurvival cytokines and activating antibodies is developed for promoting T cell expansion. These scaffolds effectively promote the proliferation of T cells, which exhibit robust antitumor capability in vitro. This research offers an ideal platform for the activation of T cells and serves as a novel approach for T cells' clinical manufacturing.